In our multicentric analysis, featuring data from five neuro‐oncology centers in Germany, we investigated the prognostic value of TMT using a homogeneous cohort of newly diagnosed MGMT promoter methylated glioblastoma patients. The gene discussed is MGMT; the disease is glioblastoma.